Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Galactosylceramidase (GALC) is a lysosomal hydrolase that catalyzes the breakdown of galactosylceramide and psychosine, essential for myelin turnover. Deficiency due to GALC mutations causes Krabbe disease, a severe demyelinating disorder. It is considered a therapeutic target, and potential therapeutic strategies include enzyme replacement therapy, gene therapy, and small molecule inhibitors.
Enzyme inhibition (potential therapeutic strategy)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Galactosylceramidase.